nach oben

Inflammation

Erschienen in:

20.03.2023 | ORIINAL ARTICLE

Inflammation Biomarker Response to Oral 2-Hydroxybenzylamine (2-HOBA) Acetate in Healthy Humans

verfasst von: John A. Rathmacher, John C. Fuller Jr, Naji N. Abumrad, Charles R. Flynn

Erschienen in: Inflammation | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Inflammation is associated with the formation of reactive oxygen species (ROS) and the formation of lipid-derived compounds, such as isolevuglandins (IsoLGs), malondialdehyde, 4-hydroxy-nonenal, and 4-oxo-nonenal. The most reactive of these are the IsoLGs, which form covalent adducts with lysine residues and other cellular primary amines leading to changes in protein function, immunogenicity, and epigenetic alterations and have been shown to contribute to a number of inflammatory diseases. 2-Hydroxybenzylamine (2-HOBA) is a natural compound found in buckwheat seeds and reacts with all IsoLG adducts preventing adduct formation with proteins and DNA. Therefore, 2-HOBA is well positioned as an agent for the prevention of inflammatory-prone diseases. In this study, we examined the potential beneficial effects of 2-HOBA on oxidative stress and inflammatory biomarkers in two cohorts of healthy younger and older adults. We utilized the Olink^® targeted inflammation panel before and after an oral 15-day treatment regimen with 2-HOBA. We found significant relative changes in the plasma concentration of 15 immune proteins that may reflect the in vivo immune targets of 2-HOBA. Treatment of 2-HOBA resulted in significant increased levels of CCL19, IL-12β, IL-20Rα, and TNFβ, whereas levels of TWEAK significantly decreased. Ingenuity Pathway Analysis identified canonical pathways regulated by the differentially secreted cytokines, chemokines, and growth factors upon 2-HOBA treatment and further points to biofunctions related to the recruitment, attraction, and movement of different immune cell types. In conclusion, 2-HOBA significantly altered the protein biomarkers CCL19, IL-12β, IL-20Rα, TNFβ, and TWEAK, and these may be responsible for the protective effects of 2-HOBA against reactive electrophiles, such as IsoLGs, commonly expressed in conditions of excessive oxidative stress. 2-HOBA has a role as a IsoLG scavenger to proactively improve immune health in a variety of conditions.

Nur mit Berechtigung zugänglich

Roth, G.A., et al. 2018. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: A systematic analysis for the Global Burden of Disease Study 2017. The Lancet 392 (10159): 1736–1788. https://doi.org/10.1016/S0140-6736(18)32203-7.CrossRef

Furman, D., et al. 2017. Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states. Nature Medicine 23 (2): 174–184. https://doi.org/10.1038/nm.4267.CrossRefPubMedPubMedCentral

Furman, D., et al. 2019. Chronic inflammation in the etiology of disease across the life span. Nature Medicine 25 (12): 1822–1832. https://doi.org/10.1038/s41591-019-0675-0.CrossRefPubMedPubMedCentral

Slavich, G.M. 2015. Understanding inflammation, its regulation, and relevance for health: A top scientific and public priority. Brain, Behavior, and Immunity 45: 13–14. https://doi.org/10.1016/j.bbi.2014.10.012.CrossRefPubMed

Netea, M.G., et al. 2017. A guiding map for inflammation. Nature Immunology 18 (8): 826–831. https://doi.org/10.1038/ni.3790.CrossRefPubMedPubMedCentral

Kotas, M.E., and R. Medzhitov. 2015. Homeostasis, inflammation, and disease susceptibility. Cell 160 (5): 816–827. https://doi.org/10.1016/j.cell.2015.02.010.CrossRefPubMedPubMedCentral

Straub, R.H. 2017. The brain and immune system prompt energy shortage in chronic inflammation and ageing. Nature Reviews Rheumatology 13 (12): 743–751. https://doi.org/10.1038/nrrheum.2017.172.CrossRefPubMed

Fullerton, J.N., and D.W. Gilroy. 2016. Resolution of inflammation: A new therapeutic frontier. Nature Reviews. Drug Discovery 15 (8): 551–567. https://doi.org/10.1038/nrd.2016.39.CrossRefPubMed

Yin, H., L. Xu, and N.A. Porter. 2011. Free radical lipid peroxidation: Mechanisms and analysis. Chemical Reviews 111 (10): 5944–5972. https://doi.org/10.1021/cr200084z.CrossRefPubMed

10.

Brame, C.J., et al. 1999. Identification of extremely reactive gamma-ketoaldehydes (isolevuglandins) as products of the isoprostane pathway and characterization of their lysyl protein adducts. Journal of Biological Chemistry 274(19): 13139–13146. http://www.ncbi.nlm.nih.gov/pubmed/10224068.

11.

Del Rio, D., A.J. Stewart, and N. Pellegrini. 2005. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutrition, Metabolism, and Cardiovascular Diseases 15 (4): 316–328. https://doi.org/10.1016/j.numecd.2005.05.003.CrossRefPubMed

12.

Klöpfer, A., R. Spanneberg, and M.A. Glomb. 2011. Formation of arginine modifications in a model system of Nα-tert-butoxycarbonyl (Boc)-arginine with methylglyoxal. Journal of Agriculture and Food Chemistry 59 (1): 394–401. https://doi.org/10.1021/jf103116c.CrossRef

13.

Carrier, E.J., et al. 2009. Characterization of covalent adducts of nucleosides and DNA formed by reaction with levuglandin. Biochemistry 48 (45): 10775–10781. https://doi.org/10.1021/bi9015132.CrossRefPubMed

14.

Galligan, J.J., et al. 2014. Stable histone adduction by 4-oxo-2-nonenal: a potential link between oxidative stress and epigenetics. Journal of the American Chemical Society 136(34): 11864–11866. http://www.ncbi.nlm.nih.gov/pubmed/25099620.

15.

Boutaud, O., et al. 1999. Characterization of the lysyl adducts formed from prostaglandin H2 via the levuglandin pathway. Biochemistry 38 (29): 9389–9396. https://doi.org/10.1021/bi990470+.CrossRefPubMed

16.

Esterbauer, H. 1993. Cytotoxicity and genotoxicity of lipid-oxidation products. The American Journal of Clinical Nutrition 57(5 Suppl): 779S-785S; discussion 785S-786S. https://doi.org/10.1093/ajcn/57.5.779S.

17.

Pollack, M., et al. 2006. Translesion DNA synthesis across the heptanone–etheno-2’-deoxycytidine adduct in cells. Chemical Research in Toxicology 19 (8): 1074–1079. https://doi.org/10.1021/tx0600503.CrossRefPubMed

18.

Carrier, E.J., et al. 2014. Levuglandin forms adducts with histone h4 in a cyclooxygenase-2-dependent manner, altering its interaction with DNA. Biochemistry 53(15): p. 2436–2441. http://www.ncbi.nlm.nih.gov/pubmed/24684440.

19.

Davies, S.S., et al. 2020. Isolevuglandins as mediators of disease and the development of dicarbonyl scavengers as pharmaceutical interventions. Pharmacological Therapy 205: 107418. https://doi.org/10.1016/j.pharmthera.2019.107418.

20.

Davies, S.S., et al. 2011. Treatment with a gamma-ketoaldehyde scavenger prevents working memory deficits in hApoE4 mice. Jornal of Alzheimers Disease 27(1): p. 49–59. http://www.ncbi.nlm.nih.gov/pubmed/21709376.

21.

Kirabo, A., et al. 2012. Activation of T cells by dendritic cells in hypertension: A potential role of isoketal-modified proteins. Hypertension 60: A166.CrossRef

22.

Tao, H., et al. 2020. Scavenging of reactive dicarbonyls with 2-hydroxybenzylamine reduces atherosclerosis in hypercholesterolemic Ldlr(-/-) mice. Nature Communications 11 (1): 4084. https://doi.org/10.1038/s41467-020-17915-w.CrossRefPubMedPubMedCentral

23.

Koyama, M., Y. Obata, and S. Sakamura. 1971. Identification of hydroxybenzylamines in buckwheat seeds. Agricultural and Biological Chemistry 35: 1870–1879.CrossRef

24.

Davies, S., et al. 2006. g-Ketoaldehyde scavengers protect against cell damage induced by tert-butylhydroperoxide. Prostaglandins & other Lipid Mediators 79: 165–165.

25.

Zagol-Ikapitte, I., et al. 2010. Characterization of scavengers of gamma-ketoaldehydes that do not inhibit prostaglandin biosynthesis. Chemical Research in Toxicology 23(1): 240–250. http://www.ncbi.nlm.nih.gov/pubmed/20041722.

26.

Pitchford, L.M., et al. 2018. Acute and 28-day repeated dose toxicity evaluations of 2-hydroxybenzylamine acetate in mice and rats. Regulatory Toxicology and Pharmacology 98(Oct): p. 190–198. https://doi.org/10.1016/j.yrtph.2018.07.026.

27.

Fuller, J.C., Jr., et al. 2018. Subchronic (90-day) repeated dose toxicity study of 2-hydroxybenzylamine acetate in rats. Regulatory Toxicology and Pharmacology 99: 225–232. https://doi.org/10.1016/j.yrtph.2018.09.025.CrossRefPubMed

28.

Fuller, J.C., Jr., et al. 2018. In vitro safety pharmacology evaluation of 2-hydroxybenzylamine acetate. Food and Chemical Toxicology 121: 541–548. https://doi.org/10.1016/j.fct.2018.09.047.CrossRefPubMedPubMedCentral

29.

Fuller, J.C., Jr., et al. 2018. Subchronic (90-day) repeated dose oral toxicity study of 2-hydroxybenzylamine acetate in rabbit. Regulatory Toxicology and Pharmacology 100: 52–58. https://doi.org/10.1016/j.yrtph.2018.10.017.CrossRefPubMed

30.

Tao, H., et al. 2020. Scavenging of reactive dicarbonyls with 2-hydroxybenzylamine reduces atherosclerosis in hypercholesterolemic Ldlr^-/- mice. Nature Communications 15. https://doi.org/10.1038/s41467-020-17915-w.

31.

Patrick, D.M., et al. 2019. A common mechanism of autoinflammation in systemic lupus erythematosus and essential hypertension. Circulation 140 (Suppl 1): A15543.

32.

Egnatchik, R.A., et al. 2017. Dysfunctional BMPR2 signaling drives an abnormal endothelial requirement for glutamine in pulmonary arterial hypertension. Pulmunary Circulation 7 (1): 186–199. https://doi.org/10.1086/690236.CrossRef

33.

Gobert, A.P., et al. 2022. The nutraceutical electrophile scavenger 2-hydroxybenzylamine (2-HOBA) attenuates gastric cancer development caused by Helicobacter pylori. Biomedical Pharmacotherapy 158: 114092. https://doi.org/10.1016/j.biopha.2022.114092.

34.

Pitchford, L.M., et al. 2019. First-in-human study assessing safety, tolerability, and pharmacokinetics of 2-hydroxybenzylamine acetate, a selective dicarbonyl electrophile scavenger, in healthy volunteers. BMC Pharmacology and Toxicology 20 (1): 1. https://doi.org/10.1186/s40360-018-0281-7.CrossRefPubMedPubMedCentral

35.

Pitchford, L.M., et al. 2020. Safety, tolerability, and pharmacokinetics of repeated oral doses of 2hydroxybenzylamine acetate in healthy volunteers: A double-blind, randomized, placebo-controlled clinical trial. BMC Pharmacology and Toxicology 21: 3. https://doi.org/10.1186/s40360-020-0382-y.CrossRefPubMedPubMedCentral

36.

Lawson, M., et al. 2017. Free Radicals and antioxidants in human disease. In nutritional antioxidant therapies: Treatments and perspectives, ed. K.H. Al-Gubory and I. Laher, 283–305. Cham: Springer International Publishing.CrossRef

37.

Lushchak, V.I. 2014. Free radicals, reactive oxygen species, oxidative stress and its classification. Chemico-Biological Interactions 224: 164–175. https://doi.org/10.1016/j.cbi.2014.10.016.CrossRefPubMed

38.

Kirabo, A., et al. 2014. DC isoketal-modified proteins activate T cells and promote hypertension. Journal of Clinical Investigation 124(10): 4642–4656. http://www.ncbi.nlm.nih.gov/pubmed/25244096.

39.

Wu, J., et al. 2016. Immune activation caused by vascular oxidation promotes fibrosis and hypertension. Journal of Clinical Investigation 126(1): 50–67. http://www.ncbi.nlm.nih.gov/pubmed/26595812.

40.

Xiao, L., et al. 2015. Renal denervation prevents immune cell activation and renal inflammation in angiotensin II-induced hypertension. Circulation Research 117 (6): 547–557. https://doi.org/10.1161/circresaha.115.306010.CrossRefPubMedPubMedCentral

41.

Zhong, J., et al. 2022. Dicarbonyl-modified lipoproteins contribute to proteinuric kidney injury. JCI Insight 7(21). https://doi.org/10.1172/jci.insight.161878.

42.

Patrick, D.M., et al. 2022. Isolevuglandins disrupt PU.1 mediated C1q expression and promote autoimmunity and hypertension in systemic lupus erythematosus. JCI Insight. https://doi.org/10.1172/jci.insight.136678.

43.

Ngwenyama, N., et al. 2021. Isolevuglandin-modified cardiac proteins drive CD4+ T-cell activation in the heart and promote cardiac dysfunction. Circulation 143 (12): 1242–1255. https://doi.org/10.1161/circulationaha.120.051889.CrossRefPubMedPubMedCentral

44.

Frei, B. 1991. Ascorbic acid protects lipids in human plasma and low-density lipoprotein against oxidative damage. American Journal of Clinical Nutrition 54 (6 Suppl): 1113s–1118s. https://doi.org/10.1093/ajcn/54.6.1113s.CrossRefPubMed

45.

Salonen, J.T., et al. 2000. Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: A randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. Journal of Internal Medicine 248 (5): 377–386. https://doi.org/10.1046/j.1365-2796.2000.00752.x.CrossRefPubMed

46.

Plantinga, Y., et al. 2007. Supplementation with vitamins C and E improves arterial stiffness and endothelial function in essential hypertensive patients. American Journal of Hypertension 20 (4): 392–397. https://doi.org/10.1016/j.amjhyper.2006.09.021.CrossRefPubMed

47.

Khanna, S., et al. 2015. Excessive α-tocopherol exacerbates microglial activation and brain injury caused by acute ischemic stroke. The FASEB Journal 29 (3): 828–836. https://doi.org/10.1096/fj.14-263723.CrossRefPubMed

48.

Gobert, A.P., et al. 2023. The nutraceutical electrophile scavenger 2-hydroxybenzylamine (2-HOBA) attenuates gastric cancer development caused by Helicobacter pylori. Biomedical Pharmacotherapy 158: 114092. https://doi.org/10.1016/j.biopha.2022.114092.

49.

Davies, S.S. 2008. Modulation of protein function by isoketals and levuglandins, in Lipids in Health and Disease, P.J. Quinn and X. Wang, Editors. Springer Publishing Company. p. 49–70.

50.

Davies, S.S., et al. 2002. Effects of reactive gamma-ketoaldehydes formed by the isoprostane pathway (isoketals) and cyclooxygenase pathway (levuglandins) on proteasome function. FASEB Journal 16(7): 715–717. http://www.ncbi.nlm.nih.gov/pubmed/11978738.

51.

Longato, L., et al. 2017. Reactive gamma-ketoaldehydes as novel activators of hepatic stellate cells in vitro. Free Radical Biology & Medicine 102: 162–173. https://doi.org/10.1016/j.freeradbiomed.2016.11.036.CrossRef

52.

McMaster, W.G., et al. 2015. Inflammation, immunity, and hypertensive end-organ damage. Circulation Research 116(6): 1022–1033. http://www.ncbi.nlm.nih.gov/pubmed/25767287.

53.

Dixon, K.B., S.S. Davies, and A. Kirabo. 2017. Dendritic cells and isolevuglandins in immunity, inflammation, and hypertension. American Journal of Physiology. Heart and Circulatory Physiology 312 (3): H368-h374. https://doi.org/10.1152/ajpheart.00603.2016.CrossRefPubMed

54.

Yoshida, R., et al. 1997. Molecular cloning of a novel human CC chemokine EBI1-ligand chemokine that is a specific functional ligand for EBI1, CCR7. Journal of Biological Chemistry 272 (21): 13803–13809. https://doi.org/10.1074/jbc.272.21.13803.CrossRefPubMed

55.

Hipkin, W. 2007. CCR7 Chemokine receptor. In xPharm: The comprehensive pharmacology reference, ed. S.J. Enna and D.B. Bylund, 1–10. New York: Elsevier.

56.

Xu, Z., et al. 2018. CCL19 suppresses angiogenesis through promoting miR-206 and inhibiting Met/ERK/Elk-1/HIF-1α/VEGF-a pathway in colorectal cancer. Cell Death & Disease 9 (10): 974. https://doi.org/10.1038/s41419-018-1010-2.CrossRef

57.

Gobert, A.P., et al. 2021. Dicarbonyl electrophiles mediate inflammation-induced gastrointestinal carcinogenesis. Gastroenterology 160 (4): 1256-1268.e9. https://doi.org/10.1053/j.gastro.2020.11.006.CrossRefPubMed

58.

Gobert, A.P., M. Asim, T.M. Smith, K.J. Williams, D.P. Barry, M.M. Allaman, K.M. McNamara, A.G. Delgado, M.B. Piazuelo, M.K. Washington, L.A. Coburn, J.A. Rathmacher, K.T. Wilson. 2023. The nutraceutical electrophile scavenger 2-hydroxybenzylamine prevents colorectal carcinogenesis and tumor growth. DDW : Chicago.

59.

Oppmann, B., et al. 2000. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13 (5): 715–725. https://doi.org/10.1016/s1074-7613(00)00070-4.CrossRefPubMed

60.

Dumoutier, L., et al. 2001. Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. The Journal of Immunology 167 (7): 3545–3549. https://doi.org/10.4049/jimmunol.167.7.3545.CrossRefPubMed

61.

Mauri, D.N., et al. 1998. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 8 (1): 21–30. https://doi.org/10.1016/s1074-7613(00)80455-0.CrossRefPubMed

62.

Ruddle, N.H. 2014. Lymphotoxin and TNF: How it all began—a tribute to the travelers. Cytokine & Growth Factor Reviews 25 (2): 83–89. https://doi.org/10.1016/j.cytogfr.2014.02.001.CrossRef

63.

Bauer, J., et al. 2012. Lymphotoxin, NF-ĸB, and cancer: The dark side of cytokines. Digestive Diseases 30 (5): 453–468. https://doi.org/10.1159/000341690.CrossRefPubMed

64.

Fernandes, M.T., E. Dejardin, and N.R. dos Santos. 2016. Context-dependent roles for lymphotoxin-β receptor signaling in cancer development. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1865(2): p. 204–219. https://doi.org/10.1016/j.bbcan.2016.02.005.

65.

Lynch, C.N., et al. 1999. TWEAK induces angiogenesis and proliferation of endothelial cells. Journal of Biological Chemistry 274 (13): 8455–8459. https://doi.org/10.1074/jbc.274.13.8455.CrossRefPubMed

66.

Burkly, L.C. 2014. TWEAK/Fn14 axis: The current paradigm of tissue injury-inducible function in the midst of complexities. Seminars in Immunology 26 (3): 229–236. https://doi.org/10.1016/j.smim.2014.02.006.CrossRefPubMed

67.

Opal, S.M., and V.A. DePalo. 2000. Anti-inflammatory cytokines. Chest 117 (4): 1162–1172. https://doi.org/10.1378/chest.117.4.1162.CrossRefPubMed

Titel: Inflammation Biomarker Response to Oral 2-Hydroxybenzylamine (2-HOBA) Acetate in Healthy Humans
verfasst von: John A. Rathmacher
John C. Fuller Jr
Naji N. Abumrad
Charles R. Flynn
Publikationsdatum: 20.03.2023
Verlag: Springer US
Erschienen in: Inflammation / Ausgabe 4/2023
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-023-01801-w

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Inflammation Biomarker Response to Oral 2-Hydroxybenzylamine (2-HOBA) Acetate in Healthy Humans

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2023

Long Non-Coding RNA-GDA-1 Promotes Keratinocyte Proliferation and Psoriasis Inflammation by Regulating the STAT3/NF-κB Signaling Pathway via Forkhead Box M1

SOCS3 Silencing Promotes Activation of Vocal Fold Fibroblasts via JAK2/STAT3 Signaling Pathway

Nintedanib Ameliorates Bleomycin-Induced Pulmonary Fibrosis, Inflammation, Apoptosis, and Oxidative Stress by Modulating PI3K/Akt/mTOR Pathway in Mice

Inhibition of NF-κB Signaling-Mediated Crosstalk Between Macrophages and Preosteoblasts by Metformin Alleviates Trauma-Induced Heterotopic Ossification

Phillygenin Ameliorates Carbon Tetrachloride-Induced Liver Fibrosis: Suppression of Inflammation and Wnt/β-Catenin Signaling Pathway

Melatonin-Driven NLRP3 Inflammation Inhibition Via Regulation of NF-κB Nucleocytoplasmic Transport: Implications for Postoperative Cognitive Dysfunction

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin